drugset / Trial / NCT00347841

Efficacy of Bimatoprost 0.03% in Patients Who Are Low-Responders to Latanoprost

NCT00347841

Phase 4 Completed Innovative Medical
Non-randomizedSingle-groupOpen-label

Summary

To evaluate the IOP-lowering efficacy of bimatoprost 0.03% in patients found to be low-responders to latanoprost therapy.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Bimatoprost Other / unclassified 0.03 %
Background Latanoprost Small molecule

Indications